PrecisionBiotics makes six presentations at Digestive Diseases Week conference (DDW) 2008. One of nine companies attending DDW 2008 with Enterprise Ireland, PrecisionBiotics seeks to build upon relationships with Procter & Gamble, ConvaTec, and Mead Johnson Nutritionals.
SAN DIEGO, CALIFORNIA, May 17, 2008 — Enterprise Ireland, the government agency responsible for the development and promotion of the indigenous business sector, today pointed to the strengthening success of client company PrecisionBiotics, based in Cork, Ireland, as a symbol of the lead role played by the country in the development of treatments for gastrointestinal disorders.
PrecisionBiotics is one of nine companies attending the DDW 2008 Conference in San Diego, California (May 17-22, 2008) as part of an official Enterprise Ireland delegation. The other eight companies are AGI Therapeutics Research Ltd. (www.agitherapeutics.com), Cellix Ltd. (www.cellixltd.com), Clinical Trial Endpoint (www.ctep.eu), Firecrest Clinical Ltd. (www.firecrestclinical.com), Opsona Therapeutics Ltd. (www.opsona.com), Pharmatrin Ltd. (www.pharmatrin.com), Sigmoid Pharma Limited (www.sigmoidbiotech.com), and Vysera Biomedical Ltd. (www.vysera.com).
"As the foundation industry partner of the Alimentary Pharmabiotic Centre at University College Cork, PrecisionBiotics is rapidly transforming research advances into commercial product breakthroughs," said Elaine Brennan, SVP Biotechnology and Pharmaceuticals, Enterprise Ireland. "These breakthroughs are now bringing relief to millions of people through strategic company partnerships with Procter & Gamble, Mead Johnson Nutritionals, and ConvaTec. We expect PrecisionBiotics to build upon these commercial successes throughout 2008 and beyond. At the same time, we expect that a number of other Irish companies will join PrecisionBiotics on center stage in the fight against gastrointestinal disorders."
Indeed, PrecisionBiotics is emphasizing a number of important milestones at the DDW 2008 Conference, according to Barry Kiely, Chief Executive Officer.
"The strengthening of our existing relationships, coupled with the addition of ConvaTec as a research and development partner, is making 2008 a seminal year for PrecisionBiotics. The efficacy and safety of PrecisionBiotics' technology places it in an excellent position to benefit from increasing market opportunities in inflammatory and gastrointestinal conditions."
Dr. Kiely said the company was extremely pleased with the progress made with its current partners Procter & Gamble (P&G) and Mead Johnson Nutritionals.
Last year, P&G expanded United States distribution of its Align® product, a daily probiotic supplement that contains PrecisionBiotics’ technology. P&G and PrecisionBiotics last year also announced the signing of an agreement that will see PrecisionBiotics' probiotic technology undergo further clinical evaluation in specific gastrointestinal indications.
"Under our on going research agreement with Mead Johnson Nutritionals, PrecisionBiotics has achieved a critical research milestone that will further enhance the relationship between the two companies.," Dr. Kiely emphasized. At the end of 2007, PrecisionBiotics signed an exclusive research and development agreement with ConvaTec, a world leader in the manufacture of ostomy and wound care products. PrecisionBiotics has also completed various pre-clinical studies and a Phase I safety trial on a new probiotic strain that shows promise in gastrointestinal indications. Last October, a study published in the American Journal of Gastroenterology and presented at the annual conference of the American College of Gastroenterology identified that bifidobacterium infantis 35624, an PrecisionBiotics lead technology, was the only probiotic to demonstrate significant improvement in IBS symptoms.
At the DDW 2008 Conference, PrecisionBiotics is presenting results from various pre-clinical abstracts. These abstracts support the research focus of PrecisionBiotics in the inflammatory and infectious disease areas.
The Role of T Cells in Vagal Protection Against Intestinal InflammationCaitlin O'Mahony, Hanneke P van der Kleij, Fergus Shanahan, John Bienenstock, Liam O'Mahony.An oral presentation on May 18, 2008
The Vexed Relationship Between Clostridium Difficile and Inflammatory Bowel Disease (IBD) - a Prospective Assessment of Carriage in An Outpatient Setting in Patients in RemissionEvelyn M Clayton, Mary C Rea, Fergus Shanahan, Eamonn M Quigley, Barry Kiely, Reynolds P Ross, Colin HillAn oral presentation on May 18, 2008
The Metabolic Activity of the Enteric Microbiota Influences the Fatty Acid Composition of Host TissuesRebecca A Wall, Reynolds P Ross, Fergus Shanahan, Liam O'Mahony, Caitlin O'Mahony, Eamonn M Quigley, Barry Kiely, Gerald Fitzgerald, Catherine StantonAn oral presentation on May 21, 2008
Mechanism of Epithelial CCL20 Response to ListeriaSinead C Corr, Ann O'Hara, Liam O'Mahony, Kenneth Nally, Fergus Shanahan, Colin Hill, Cormac G Gahan. A poster presentation on May 19, 2008
Bifidobacteria Attenuate the Development of Non-Alcoholic Fatty Liver in Obese MiceAhmed A Abu-Shanab, Eileen F Murphy, Erin L Symonds, Mohammed T Badr, Liam O'Mahony, Fergus Shanahan, Brendan M Buckley, Eamonn M QuigleyA poster presentation on May 19, 2008
In Vivo Imaging of a Probiotic-Mediated Regulatory T Cell Response Following Adoptive Transfer Caitlin O'Mahony, Paul Scully, David O'Mahony, Sharon Murphy, Frances O'Brien, Anne Lyons, Barry Kiely, Fergus Shanahan, Liam O'Mahony A poster presentation on May 18, 2008
About PrecisionBiotics Ltd
PrecisionBiotics Ltd. is a development stage specialty biotechnology company focused on the discovery, development and commercialization of proprietary probiotic and pharmabiotic treatments for gastrointestinal disorders and other inflammatory conditions. The company is the foundation industry partner of the Alimentary Pharmabiotic Centre based at University College Cork, ("UCC") Ireland. Enterprise Ireland is the government agency responsible for the development and promotion of the indigenous business sector.
Enterprise Ireland's mission is to accelerate the development of world-class Irish companies to achieve strong positions in global markets resulting in increased national and regional prosperity.
Contact: Bob Griffin, Griffin Integrated Communications (212) 481-3456 x16 email@example.com